An observational study in Essential Hypertension, sponsored by Hasten Biopharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-01.
Sponsored by Hasten Biopharmaceutical Co., Ltd. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Essential Hypertension with a site in China — 19 open to participants now, 20 under way, 2 of them phase 3. Essential Hypertension · China.
Among the 76 studies in Essential Hypertension with a site in China, this one is one of 8 that started in 2024, is one of 9 observational ones, reaches primary completion later than 4 of the 19 other live ones, and was the 52nd registered.
481 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.
Browse Essential Hypertension studies →19 of the 76 studies in Essential Hypertension with a site in China are open now. Recruiting first, the newest first:
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18+
Beijing Anzhen Hospital · Sites in China
Ages 18–65
Shanghai Minwei Biotechnology Co., Ltd · Sites in China
Ages 18–60 · Healthy volunteers
Suzhou Alphamab Co., Ltd. · Sites in China
Ages 18–65
Lepu Medical Technology (Beijing) Co., Ltd. · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 43 Essential Hypertension studies recruiting now, 15 (35%) set no upper age limit and 20 (47%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 18 · Phase 4 14
First in 2004; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,215 is above the median of 718 across 71 observational studies indexed under Essential Hypertension.
Median enrollment 297 across the 67 interventional studies, 2,000 across the 9 observational. Of the 33 that completed or were terminated, 7 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 76 have an industry lead sponsor. The 10 most frequent:
Hasten Biopharmaceutical Co., Ltd. is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Hasten Biopharmaceutical Co., Ltd. has 1 study filed under Essential Hypertension — fewer than ten, so there is no comparison to draw.
5 of the studies in Essential Hypertension with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07191899Suzhou Alphamab Co., Ltd.To Evaluate the Efficacy and Safety of KN060 in Essential Hypertension | 2026-12-30 |
| NCT06059638Orchestra BioMed, IncBradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT | 2027-01 |
| NCT07940075CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.SYH2062 Injection in Participants With Mild to Moderate Essential Hypertension . | 2027-01-31 |
| NCT07577323Xuanwu Hospital, BeijingSafety and Efficacy Evaluation of Non-invasive Temporal Interference Stimulation for Blood Pressure Modulation in Patients With Mild Essential Hypertension | 2027-05-31 |
| NCT07566650Xuanwu Hospital, BeijingHigh-Intensity Transcranial Alternating Current Stimulation (Hi-tACS) for Hypertension: A Randomized Controlled Trial | 2027-10-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 76 studies in Essential Hypertension with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a national multicenter, prospective, observational study. It is planned to enroll 1215 patients with newly diagnosed essential hypertension in 80 centers, and divide them into 3 groups according to different treatment plans given by doctors: AZL-M monotherapy group, CCB monotherapy group (amlodipine besylate tablets or nifedipine controlled-release tablets) and AZL-M+CCB (amlodipine besylate tablets or nifedipine controlled-release tablets) combined treatment group. Subjects were visited 4 times at baseline, 1 month, 3 months, and 6 months, and the following key indicators of subjects were measured according to the doctor's decision, and the measurement results were collected
town hospital
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Azilsartan Medoxomil Potassium Tablet,80mg,tablet,QD,six months
Drug: Azilsartan Medoxomil Potassium Tablet
Nifedipine Controller-release Tablets,clinical maximum tolerated dose,tablet,QD,six months;or Levoamlodipine Maleate Table,clinical maximum tolerated dose,tablet,QD,six months; Doctor choose a medication that is more suitable for patient treatment.
Drug: Nifedipine Sustained -release Tablets · Drug: Levoamlodipine Maleate Table
Nifedipine Controller-release Tablets,clinical maximum tolerated dose,tablet,QD,six months;and Levoamlodipine Maleate Table,clinical maximum tolerated dose,tablet,QD,six months; When the patient's upper pressure exceeds 160 Millimetre of mercury, the doctor will choose combination medication .CCB drug will be chosen either Nifedipine Controller-release Tablets or Levoamlodipine Maleate Table.
Drug: Azilsartan Medoxomil Potassium Tablet · Drug: Nifedipine Sustained -release Tablets · Drug: Levoamlodipine Maleate Table
Azilsartan Medoxomil Potassium Tablet,80mg,qd,lasts six month
Nifedipine Sustained -release Tablets,qd,The maximum clinical dose,lasts six months;
Levoamlodipine Maleate Table,qd,The maximum clinical dose,lasts six months;
the patient's blood pressure reached the target rate
Ø Compliance rate of systolic blood pressure (SBP) in the clinic: the proportion of subjects whose blood pressure dropped to sitting systolic blood pressure (sitSBP) \<140 mmHg or compared with the baseline value of sitSBP ≥ 20mmHg; Ø Compliance rate of diastolic blood pressure (DBP) in the clinic: the proportion of subjects whose blood pressure dropped to sitting diastolic blood pressure (sitDBP) \<90 mmHg or compared with the baseline value of sitDBP decreased by ≥10mmHg; Ø Achievement rate of both SBP and DBP in the clinic: the proportion of subjects who meet the SBP and DBP standards in the above clinics at the same time.
Time frame: 6 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Jun 2025, 17 months after the start.
Of 27 observational studies under Essential Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 52. This study's planned 17 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hasten Biopharmaceutical Co., Ltd.